Learn more: PMC Disclaimer | PMC Copyright Notice
This article has been retracted.
Increased muscle PGC-1α expression protects from sarcopenia and metabolic disease during aging
Associated Data
Abstract
Aging is a major risk factor for metabolic disease and loss of skeletal muscle mass and strength, a condition known as sarcopenia. Both conditions present a major health burden to the elderly population. Here, we analyzed the effect of mildly increased PGC-1α expression in skeletal muscle during aging. We found that transgenic MCK-PGC-1α animals had preserved mitochondrial function, neuromuscular junctions, and muscle integrity during aging. Increased PGC-1α levels in skeletal muscle prevented muscle wasting by reducing apoptosis, autophagy, and proteasome degradation. The preservation of muscle integrity and function in MCK-PGC-1α animals resulted in significantly improved whole-body health; both the loss of bone mineral density and the increase of systemic chronic inflammation, observed during normal aging, were prevented. Importantly, MCK-PGC-1α animals also showed improved metabolic responses as evident by increased insulin sensitivity and insulin signaling in aged mice. Our results highlight the importance of intact muscle function and metabolism for whole-body homeostasis and indicate that modulation of PGC-1α levels in skeletal muscle presents an avenue for the prevention and treatment of a group of age-related disorders.
Aging is a multifactorial condition characterized by energetic deficits and decreased stress tolerance resulting in tissue degeneration and malfunction. One of the major tissues affected during aging is skeletal muscle. Besides being fundamental for movement and mobility, skeletal muscle is also crucial for overall energy balance and metabolism (1). Aging causes a gradual loss of skeletal muscle mass, a condition known as sarcopenia (2). This age-associated muscle wasting results in muscle weakness and hence has a significant effect on physical activity and life quality in the elderly. While the exact causes of sarcopenia are not clear, and multiple factors likely define the disease mechanism (3), several lines of evidence suggest mitochondrial involvement in this degenerative condition (4). Apoptosis as well as autophagy have been implicated in the disease mechanism (4). Therapeutic strategies for sarcopenia like endurance exercise (5) and caloric restriction (4) result in increased mitochondrial capacity in the muscle suggesting that mitochondrial dysfunction has a critical role in the muscle loss.
A key player controlling mitochondrial function is the peroxisome proliferator-activated receptor γ coactivator α (PGC-1α), a master regulator of mitochondrial biogenesis (6). In skeletal muscle, PGC-1α can also prevent muscle wasting by regulating autophagy (7) and stabilization of the neuromuscular junction (NMJ) program (8) in the context of muscle atrophy during disease. Thereby, PGC-1α links mitochondrial function to muscle integrity (7). PGC-1α levels in skeletal muscle decrease during aging (9). The health promoting effects of increased PGC-1α expression in skeletal muscle could be shown in different mouse models with affected muscle such as Duchenne muscular dystrophy (8), denervation-induced atrophy (7), and mitochondrial myopathy (10).
Results
Increased PGC-1α Expression in Muscle Prevents Age-Associated Weight Gain and Improves Exercise Capacity.
We have recently shown that activation of PGC-1α delays the onset of a myopathy caused by a mitochondrial dysfunction and extends life span and health span, most likely by increasing overall ATP generating capacity (10, 11). Here, we tested if elevated PGC-1α expression in muscle has a beneficial effect on the development and progression of sarcopenia and its metabolic consequences. Therefore, we studied muscle aging in a mouse model with a MCK-PGC-1α transgene, which is expressed in all skeletal muscles and results in PGC-1α protein levels equal to those found endogenously in type 1 muscle (6). Here, we observed that the MCK-PGC-1α animals did not show the age-associated weight gain observed in the wild-type control animals (Fig. 1A and Fig. S1A). At 22 months of age, MCK-PGC-1α animals had ≈18% reduction in fat mass and ≈8% increase in lean mass compared to their age-matched control littermates (Fig. 1 B and C). We further observed that the hind limb muscle mass relative to the body weight was significantly decreased in the aged wild-type animals compared to their age-matched MCK-PGC-1α littermates (Fig. 1D), indicating that PGC-1α might be in involved in regulating muscle mass during aging. Expression of PGC-1α also improved the exercise performance during aging as evidenced by increased endurance (Fig. S1B) and improved performance in a high-performance exercise test compared to wild-type animals (Fig. 1E), indicating improved muscle function in the aging MCK-PGC-1α mice. Increased PGC-1α expression was reported to increase endurance capacity in young mice (10, 12). Importantly, we also observed that MCK-PGC-1α animals had increased levels of bone mineral density compared to their aging wild-type littermates (Fig. S1C), most likely because of the improved muscle function in the transgenic animals (13). Moreover, we observed a longer lifespan in MCK-PGC-1α mice (Fig. S1D). Studies of larger groups of animals will be to be necessary to define the extent and significance of this life-prolonging effect. We also observed that the expression of the NAD+ deacetylase Sirt1, which is implicated in longevity (14), is significantly increased in muscle from MCK-PGC-1α mice (Fig. S1E).
Increased PGC-1α expression in skeletal muscle prevents age-associated weight gain and improves exercise capacity during aging. (A) Comparison of mice expressing the PGC-1α transgene in skeletal muscle (MCK-PGC-1α) and wild-type littermates (control) at different ages. (B and C) Lean and fat mass of 22-month-old wild-type and PGC-1α animals as determined by DEXA scans (n = 6 for each group). *, P > 0.05. (D) Relative hindlimb mass of 22-month-old wild-type and PGC-1α animals (n = 6 for each group). *, P > 0.001. (E) Treadmill performance test at different ages for wild-type and PGC-1α animals (n = 9 for each group). *, P > 0.001. In this and all subsequent figures, error bars represent SD.
Elevated PGC-1α Levels Increases Mitochondrial Mass and Preserve Mitochondrial Oxidative Phosphorylation Capacity in Muscle During Aging.
We next analyzed the effect of PGC-1α expression on mitochondrial function during aging by assessing the specific activity of different mitochondrial enzymes in skeletal muscle mitochondria and homogenates. At 3 months of age, no significant differences in the oxidative phosphorylation (OXPHOS) enzyme cytochrome c oxidase (COX) in mitochondria were observed between wild-type and MCK-PGC-1α animals. Samples obtained from 12-month-old wild-type animals showed a decline in COX activity, while samples obtained from age-matched MCK-PGC-1α animals maintained their COX activity. At 22 months of age, wild-type samples had only ≈60% of the COX activity observed in the younger animals, whereas samples derived from MCK-PGC-1α animals were virtually indistinguishable from those of 3-month-old animals (Fig. 2A). Similar results were obtained for the mitochondrial matrix protein citrate synthase (CS) (Fig. S2A) and OXPHOS complexes I+III (CI+III) (Fig. S2B).
Increased PGC-1α expression in skeletal muscle preserves OXPHOS function on organelle basis and increases overall OXPHOS capacity. (A and B) Relative COX activity in skeletal muscle mitochondria (A) and muscle homogenates (B) at different ages (n = 9 for each mouse group). *, P < 0.05, **, P < 0.001. (C and D) Western blot of NDUFA9, flavoprotein (Fp), COXI, ATPase β, VDAC1, and α-tubulin in skeletal muscle mitochondria (C) and muscle homogenates (D) of 3- and 22-month-old mice. (E) Histology of biceps femoris muscle from MCK-PGC-1α and wild-type control mice at 3 and 22 months showing succinate dehydrogenase (SDH), COX, and combined COX/SDH activity staining. (F and G) Levels of serum lactate and skeletal muscle ATP before and after exercise (n = 3 for each mouse group). *, P < 0.05, **, P < 0.001.
When assessing mitochondrial enzymes in muscle homogenates, samples from MCK-PGC-1α animals had increased activities: At 3 months of age, COX activity in muscle homogenates from MCK-PGC-1α animals was ≈1.5-fold increased over activitiy observed in wild-type controls (Fig. 2B). Increased CS and CI+III activities were also observed at this age in muscle homogenates. Since COX, CS, and CI+III activity in mitochondria at 3 months is not significantly different between MCK-PGC-1α and wild-type, the increase in the activity can be attributed to an increase in mitochondrial mass induced by the PGC-1α expression. In both MCK-PGC-1α and wild-type animals, COX activity declined over time. This decline was more pronounced in muscle homogenates from wild-type samples, where COX activity decreased at 12 months of age to ≈60% of the activity seen in 3-month-old wild-type animals and decreased further to ≈30% at 22 months of age. A similar decline in muscle COX activity was reported before during aging (15). In contrast, at 12 months of age, muscle homogenates from MCK-PGC-1α animals had ≈140% of COX activity observed in 3-month-old control animals and ≈100% at 22 months of age. Similar trends were observed for CS and CI+III activities in muscle homogenates (Fig. S2 C and D).
The observed decrease in OXPHOS in muscle mitochondria and homogenates during aging in wild-type animals was also evident in Western blots. When mitochondria and muscle homogenates were probed for different subunits of the individual OXPHOS complexes, samples from aged wild-type animals showed decreased levels of the probed subunits compared to the young wild-type animals. Samples from aged MCK-PGC-1α animals showed little or no decline in subunit levels compared to the young MCK-PGC-1α samples (Fig. 2 C and D). Histochemical staining of muscle sections were in agreement with this finding of preserved mitochondrial function in aging MCK-PGC-1α mice (Fig. 2E). Maintenance of oxidative capacity also allowed the aged MCK-PGC-1α animals to support their ATP demand during exercise training comparable to young animals. Aged wild-type animals showed a dramatic increase in serum lactate levels and ATP depletion in muscle after exercise, indicating their susceptibility to metabolic stress caused by the declined mitochondrial function (Fig. 2 F and G).
RT-PCR experiments using skeletal muscle cDNA from 3- and 22-month-old wild-type mice revealed that PGC-1α levels declined during aging by >60% (Fig. S2E). In addition, mitochondrial transcription factor A (TFAM) and nuclear respiratory factor 1 (NRF1), key transcription factors in mitochondrial biosynthesis (16), are also reduced during aging (Fig. S3E). We also observed a decrease in a mitochondrial ribosome component suggesting a concomitant decrease in mitochondrial protein synthesis (Fig. S2F).
Increased PGC-1α Levels in Aging Muscle Enhances Anti-Oxidant Defense and Prevents Oxidative Damages.
Maintenance of functional mitochondria relies on coordination of mitochondrial biogenesis and degradation. The observed decrease in factors regulating mitochondrial biogenesis in the aged wild-type animals prompted us to analyze whether this decline causes accumulation of damaged cellular structures and/or change in degradative processes. We observed increased oxidized nucleic acids in the aged wild-type as evidenced by immunodetection of 8-OH-guanosine in skeletal muscle sections in contrast to aged MCK-PGC-1α animals, which showed only weak staining (Fig. 3A). When analyzing the anti-oxidant response, we observed that young and aged MCK-PGC-1α animals expressed higher levels of superoxide dismutase 2 (SOD2) in their skeletal muscle mitochondria compared to wild-type controls at all ages (Fig. 3B) and showed a 2.5- to 3-fold increase in catalase activity compared to wild-type samples (Fig. 3C). In aged wild-type samples, a decrease in the SOD2 levels and catalase activity compared to the young wild-type samples is evident (Fig. 3 B and C), in agreement with the decrease in mitochondrial proteins observed before. While there is also a slight decrease in SOD2 and catalase in aged vs. young MCK-PGC-1α mice, the levels are still largely preserved compared to the aged wild-type samples and presumably could prevent the oxidative damage. Decreased oxidative protein modification in the aged MCK-PGC-1α skeletal muscle homogenates compared to the aged wild-type could also be seen as increased protein carbonylation (Fig. S3). Activation of PGC-1α was previously shown to increase the anti-oxidant response in young animals and thus prevent the oxidative damage associated with muscle damage (11).
Increased PGC-1α expression during aging results in increased anti-oxidant response, lowered inflammatory markers, and preserved muscular structure. (A) Immunohistochemistry of mice biceps femoris using anti-8-OH-guanosine antibody to detect oxidative damage to nucleic acids. (B) Western blot of SOD2, HSP70, and VDAC1 in skeletal muscle mitochondria. (C) Catalase activity in muscle mitochondria (n = 9 for each group). *, P < 0.001. (D) Quantification of regenerating fibers in biceps femoris based on the number of fibers with centered nuclei (Fig. S3C) (n = 6 for each group). *, P < 0.05. (E) Level of inflammatory markers in skeletal muscle (n = 9 for each group). *, P < 0.01. (F) Western blot of p65-NFκB and α-tubulin in skeletal muscles homogenates of 3- and 22-month-old mice. (G) NMJs stained with Alexa-555 α-bungarotoxin to label AChR and Alexa-488 Fasciculin2 to label AChE to visualize the NMJ. (H) Sucrose gradient profiles of AChE activity show the different oligomeric forms of AChE expressed in young and older animals. G1, G2, and G4 are the globular monomeric, dimeric, and tetrameric AChE forms, respectively. A8 and A12 indicate the positions of the asymmetric collagen tailed synaptic forms.
MCK-PGC-1α Mice Have Preserved Muscle Integrity and NMJ.
Overall, the transgenic MCK-PGC-1α expression had a beneficial effect on muscle integrity. In the aged wild-type animals, serum creatine kinase levels were significantly increased, while the levels in aged MCK-PGC-1α animals were within the range observed in the young mice samples (Fig. S4A). As evident from the hematoxylin and eosin (H&E) staining of muscle sections from young and aged wild-type and MCK-PGC-1α animals, aged wild-type animals showed increased number of fibers with centered nuclei, indicating regenerating fibers (Fig. 3D and Fig. S4B). The aged wild-type animals also showed greatly increased inflammatory markers TNFα and IL-6 in skeletal muscle compared to their age-matched MCK-PGC-1α littermates (Fig. 3E) indicating severe tissue damage. RT-PCR experiments revealed, that already at 3 months of age, MCK-PGC-1α had slightly lowered levels of the cytokines (Fig. S4C). As a response to the proinflammatory stimuli, NFκB is phosphorylated and translocated from cytoplasm to the nucleus to initiate transcriptional response (17). In agreement, the levels of the phosphorylated p65 NFκB subunit were significantly increased in the muscle of wild-type animals, whereas only very low levels of p65 NFκB could be detected in MCK-PGC-1α animals at all ages (Fig. 3F). Interestingly, we observed that aged MCK-PGC-1α mice had lower serum TNFα and IL-6 levels compared to controls (Fig. S4D). We also observed that skeletal muscle from aged wild-type mice showed increased collagen deposition indicative of fibrosis as a result of the muscle dysfunction. In contrast, in muscle of MCK-PGC-1α mice, less collagen deposition was observed suggesting that the elevated PGC-1α levels attenuate age-related muscle fibrosis (Fig. S5).
Because PGC-1α is involved in NMJ remodeling (8), we analyzed whether its expression in skeletal muscle influences NMJ organization and acetylcholinesterase (AChE) expression during aging. In both wild-type and MCK-PGC-1α mice, we observed an increase in segmentation in NMJs related to aging (18) (Fig. 3G). However, the area comprising the NMJ was significantly larger by ≈50% (Fig. S6), with a parallel increase in levels of AChE and acetylcholine receptors (AChR). The density of AChR at the NMJs was particularly elevated (Fig. S6). In addition, there were also significant changes in the pattern of AChE oligomeric forms expressed (Fig. 3H). Although there was little or no change in the expression of the monomeric (G1) and dimeric (G2) newly-synthesized endoplasmic reticulum resident forms of the enzyme, there was a dramatic age-related decrease in the asymmetric A8 and A12 AChE forms consisting of two to three tetramers of catalytic subunits, which are the major ones localized to the NMJ (19). The pattern of AChE forms expressed in MCK-PGC-1α mice more closely resembled the pattern of enzyme expressed in young mice muscles, indicating that the increased expression of PGC-1α is muscle maintained synaptic proteins, and hence function, in a younger state.
Increased PGC-1α Expression During Aging Attenuates Degradative Processes Associated with Muscle Atrophy.
Degradative processes such as apoptosis and autophagy have been implicated in muscle atrophy and sarcopenia (4). PGC-1α has been suggested to have anti-apoptotic effects (20) and has been identified as a negative regulator of autophagy in skeletal muscle (7) Here we show that increased PGC-1α levels in skeletal muscle are also protective against degradative processes during aging. When analyzing the frequency of apoptotic events, we saw a clear increase in active caspase 3 in aged wild-type muscle both by immunostaining (Fig. 4A) and by Western blot analysis (Fig. S7B), while no significant increase in active caspase 3 was observed in aging MCK-PGC-1α muscle (Fig. 4A and Fig. S7B). We further analyzed DNA fragmentation in muscle at different ages for both wild-type and MCK-PGC-1α mice. We observed a significant increase in this apoptotic index in wild-type skeletal muscle starting at 12 months of age (Fig. 4B). While the levels of DNA fragmentation also increased in MCK-PGC-1α animals, this increase was ≈50% lower than in the wild-type muscles (Fig. 4B). This protective effect was also evident in the preserved Bcl2:Bax ratios in skeletal muscle of MCK-PGC-1α animals. In contrast, the Bcl2:Bax ratio declined during aging in the wild-type muscle thereby favoring apoptotic events (Fig. 4C and quantification in Fig. S7A). We also observed increases in the levels of Bax, and to a lesser extent Bcl2, in both aging wild-type and PGC-1α animals.
Increased PGC-1α levels in aging muscle prevent degradative processes (A) Immunohistochemistry of biceps femoris using anti-active caspase 3 antibody to detect apoptosis. (B) Apoptotic index in skeletal muscle homogenates of wild-type and MCK-PGC-1α of different age-groups based on nucleosome fragmentation (n = 6 for each group). *, P < 0.05, **, P < 0.01, ***, P < 0.001. (C) Western blot of Bax and Bcl-2 in skeletal muscle homogenates. (D) Western blot of the 20S subunit of the proteasome and tubulin in skeletal muscle homogenates. (E) Western blot of LC3-I and LC3-II in skeletal muscle homogenates.
We next used RT-PCR experiments to analyze the expression of genes associated with muscle atrophy. We found increased expression of ubiquitin ligases and autophagy related genes in aging wild-type muscle, while expression in the MCK-PGC-1α samples remained unchanged or only slightly increased (Fig. S7C). Therefore, we further analyzed both degradative processes during aging. We observed a large increase in the 20S proteasome subunit in aged wild-type muscles compared to aged-matched MCK-PGC-1α and young wild-type muscles (Fig. 4D). We also observed a minor increase in the levels of 20S proteasome subunit in the aged MCK-PGC-1α samples compared to the young MCK-PGC-1α ones (Fig. 4D). We also observed less ubiquitinylation in samples from aged MCK-PGC-1α mice compared to aged wild-type controls (Fig. S7E). We then analyzed alterations in autophagy during skeletal muscle aging by studying the microtubule-associated protein light chain 3 (LC3). The cytosolic form, called LC3-I, is further converted to an autophagosome-associating form, LC3-II. Therefore, the protein level of LC3-II is often used as a measure to determine autophagic activity (21). Western blot analysis of the LC3-I and LC3-II isoforms revealed, that the LC3-II:LC3-I ratio increases significantly during aging in wild-type muscle, whereas no significant increase was observed in the MCK-PGC-1α samples (Fig. 4E, quantification in Fig. S7D) emphasizing the regulatory role of PGC-1α in autophagy. Notably, the FoxO proteins, which control autophagy in skeletal muscle, have been shown to be activated by reactive oxygen species (ROS) and TNFα (22). Hence, the increase anti-oxidant defense and decreased TNFα levels in the aging MCK-PGC-1α mice might also contribute to prevent dysregulated autophagy. Our results indicate that during muscle aging, PGC-1α reduces autophagy, presumably similarly as in muscle wasting diseases (7), and protects muscle from proteolysis and apoptosis.
Muscle-Specific PGC-1α Expression Prevents Age-Associated Insulin Resistance and Improves Muscular Insulin Signaling.
We next addressed whether the preserved muscle function in aging MCK-PGC-1α mice had an effect on overall metabolism. Loss of the metabolic quality in the aging muscle is a major risk factor for the development of insulin resistance and diabetes during aging (1). We found that MCK-PGC-1α animals had increased glucose tolerance and increased insulin sensitivity compared to age-matched wild-type animals (Fig. 5 A and B). In addition, we found that aged MCK-PGC-1α animals had lower fasting blood glucose levels (Fig. S8A). This difference in insulin sensitivity is clearly induced by the aging process, since no differences between MCK-PGC-1α and wild-type animals were detected at 3 months of age when fed a regular diet (Fig. S8 B and C). Thus, elevated muscle-specific PGC-1α expression seems to be protective for age-associated insulin resistance. Interestingly, young MCK-PGC-1α transgenic mice were more prone to fat-induced insulin resistance due to decreased insulin-stimulated muscle glucose uptake (23). These findings suggest that PGC-1α has different effects in diet-induced versus age-associated insulin resistance. We also observed that aged MCK-PGC-1α animals had unchanged serum triglyceride levels, whereas aged wild-type animals had significantly increased triglyceride levels indicative of the imbalanced metabolism (Fig. 5C). Clearly the preserved muscle function and muscle mass are major contributors to the increased insulin sensitivity in the aged MCK-PGC-1α mice. We further assessed whether increased expression of PGC-1α during aging also affected insulin signaling. We analyzed insulin signaling by assaying phosphorylation of two components of the insulin signaling pathway, Akt and mTOR. We found that levels of phospho-Akt (pAkt) and phospho-mTOR (pmTOR) did not significantly decrease during aging in the MCK-PGC-1α mice (Fig. 5D). In contrast, pAkt and pmTOR levels were already decreased in the young wild-type animals compared to the age-matched MCK-PGC-1α mice and dropped even further during aging (Fig. 5D). These findings indicate increased and robust insulin signaling in the MCK-PGC-1α mice during aging, whereas the insulin signaling is attenuated in the older wild-type animals. Akt and mTOR are key players in regulating muscle integrity; Akt, along with PGC-1α is a negative regulator of the FoxO proteins that control protein degradation, whereas mTOR is a modulator of protein synthesis in muscle (24). Hence, the improved insulin signaling plus the regulatory function of PGC-1α on protein degradation in the aged MCK-PGC-1α mice prevents the excessive protein degradation observed in the wild-type animals, where negative regulation of the FoxO proteins is reduced, presumably contributing to the age-associated muscle wasting. Improved insulin sensitivity and improve insulin action is suggested to be a key mechanism in the life-prolonging effect of caloric restriction (25). Intriguingly, while caloric restriction is a systemic approach, we see similar effects in the MCK-PGC-1α mice. We further observed that, in both young and aged MCK-PGC-1α animals, vascularization of the muscle was greatly increased compared to the wild-type animals, as evident in the activity stain for the endothelial vascular structure (Fig. S9). The increased blood supply contributes to the improved muscular function (26) as well as improved muscle metabolism as previously reported (27).
Increased PGC-1α expression in skeletal muscle during aging improves insulin signaling and vascularization, resulting in improved glucose and insulin tolerance. (A) Glucose tolerance test in 22-month-old wild-type and MCK-PGC-1α animals (n = 9 for each group). *, P < 0.05, **, P < 0.01. (B) Insulin tolerance test in 22-month-old animals (n = 9 for each group). *, P < 0.05, **, P < 0.01, ***, P < 0.001. (C) Quantification of circulating triglyceride levels (n = 9 for each group). *, P < 0.01. (D) Western blot of pAkt/Akt, pmTOR/mTOR, and tubulin in skeletal muscle homogenates.
Discussion
Mitochondrial dysfunction has been implicated in many age-related diseases (14). In particular, OXPHOS function declines with age in multiple tissues (28). Hence, mitochondria seem to be a prime target for anti-aging interventions (14). We could previously show that elevated PGC-1α expression in skeletal muscle enhanced OXPHOS function in a mouse model of mitochondrial myopathy, delaying the onset of the myopathy and markedly prolonging lifespan (10). This finding prompted us to investigate if elevated PGC-1α expression can also compensate for the age-associated decline of OXPHOS function in muscle. Intriguingly, we found that in MCK-PGC-1α animals Sirt1 expression was increased compared to wild-type controls suggesting a positive feedback mechanism. Sirt1 is known to activate PGC-1α by deacetylation (29), and while the detailed mechanisms of this feedback regulation remain unclear, our findings suggest that Sirt1/PGC-1α form a regulatory axis to control mitochondrial function during aging. This positive feedback may also contribute to some of the anti-aging effects observed.
We found that increased PGC-1α expression buffered against the decline in OXPHOS function during aging thereby preserving metabolic fitness and exercise capacity. Unexpectedly, we found that PGC-1α expression not only increases mitochondrial biogenesis but also maintains OXPHOS function at the mitochondrial level during aging. Hence, the observed overall enhancement in OXPHOS capacity in the MCK- PGC-1α mice is the sum of an increased mitochondrial mass and increased mitochondrial function.
Sarcopenia is associated with increased apoptosis, autophagy, and proteolysis (4). Elevated PGC-1α expression in muscle during aging decreased these degradative processes, which presumably preserved muscle integrity and muscle mass. In addition, we observed that MCK-PGC-1α mice had “functionally younger” NMJ, which together with the enhanced ATP generating capacity and muscle integrity preserved muscle function during aging. MCK-PGC-1α mice also showed less muscle fibrosis than wild-type mice during aging. Fibrosis is supposedly driven by the repeated bouts of muscle-fiber degeneration and ensuing inflammation, such as in Duchenne muscular dystrophy (30). During aging, there is increased collagen deposition and fibrosis (31). It seems likely, that elevated PGC-1α expression in muscle might protect from the age-associated fibrosis by maintaining muscle integrity and preventing an inflammatory response. In agreement, increased muscle PGC-1α expression ameliorates a dystrophin-deficient phenotype in mice (8).
We also observed that muscle from MCK-PGC-1α mice had increased anti-oxidant defense and less oxidative damage compared to their wild-type littermates. Higher anti-oxidant levels and less ROS have been implicated in longevity (14). Moreover, accumulation of damaged cellular structures such as oxidized proteins and lipids trigger degradative processes such as autophagy, apoptosis, and proteolysis, which, when becoming excessive, are detrimental for cellular survival. In addition, degradation of damaged structures requires de novo synthesis to replenish and maintain cellular function. The elevated PGC-1α expression in muscle stimulates mitochondrial biogenesis and might thus facilitate mitochondrial turnover, so that damaged organelles do not accumulate and the mitochondria remain in a “functionally younger” state.
Intriguingly, we found that the maintenance of muscle integrity and metabolic function in the MCK-PGC-1α mice had systemic effects. Chronic inflammation is a major underlying condition of the aging process (32). Here, we could show that mildly elevate expression of PGC-1α in muscle modulates this inflammatory response not only in the muscle itself, but also systemically. Elevated circulating inflammatory markers can also damage other tissues unrelated to the primary damaged organ (33) and are prognostic for many age-related diseases, such as cardiovascular disease, diabetes, and dementia (34–36). Hence, increased muscle-specific PGC-1α expression seems to improve whole-body health by maintaining muscular integrity and thus preventing a systemic inflammatory response.
In addition, MCK-PGC-1α mice did not show the age-associated weight gain, loss of bone mineral density, and most importantly, did not develop age-related insulin resistance. These results can be attributed to the preserved metabolic processes and muscle function in the MCK-PGC-1α mice. PGC-1α and its target genes are down-regulated in human diabetes (37). Our results imply that increasing PGC-1α in muscle can compensate for this down-regulation and prevent insulin resistance in mice. Interestingly, resveratrol-induced PGC-1α expression also protected from diet-induced diabetes (38). These findings clearly underscore the importance of muscle function for whole body homeostasis.
In conclusion, our results indicate that increased muscle PGC-1α expression not only prevents the age-associated muscle wasting and dysregulated muscle metabolism underlying sarcopenia, but has also a significant beneficial effect on whole-body metabolism. Preservation of muscle integrity by preventing the decline in mitochondrial function, the NMJ structure, and excessive degradative processes during aging improves insulin sensitivity and insulin action. Additionally, this protection of muscle integrity also prevents the age-related increase of circulating cytokines, which are prognostic for disease development and death during aging. Interestingly, these findings support the concept that the anti-aging effects of SIRT1 are mediated, at least in part, by a metabolic remodeling that involves increased mitochondrial biogenesis (14). These robust effects clearly identify PGC-1α activation not only as a therapeutic target for treatment of sarcopenia and age-related muscle metabolic disorders, but also highlights the importance of muscle function for whole-body metabolism and health.
Materials and Methods
Animal Husbandry.
The mice expressing PGC-1α in skeletal muscle were described in ref. 6. Mice used in the different experimental groups were littermates, and their background was ≈94% C57BL6 and 6% 129svj. The mice were kept in a condition of 12-h light/dark cycle at room temperature. They were allowed a regular diet (Rodent Chow 5010, Harlan) ad libitum.
Phenotyping.
Treadmill performance and endurance tests were carried out as described in ref. 10. Blood, body composition measurements, and pathological stainings are described in SI Text.
Mitochondrial Function and Composition.
Enzyme activities and Western blots were performed as described in ref. 10. The list of antibodies used is described in SI Text.
Data Analysis.
Data obtained are represented as mean (+ SD) from three to seven mice per group, and statistical significance was determined using the Student's t test. A P value < 0.05 was considered significant.
Additional Experimental Procedures.
The detailed additional procedures are described in SI Text.
Acknowledgments.
This work was supported by Public Health Service Grants NS041777, CA85700, and EY10804 (to C.T.M.); AG0005917 (to R.L.R.); and DK61562 and DK54477 (to B.M.S.); the Muscular Dystrophy Association (C.T.M.); and the Ellison Foundation (B.M.S.). Dr. Wenz was supported by a fellowship from the United Mitochondrial Disease Foundation.
Footnotes
The authors declare no conflict of interest.
This article contains supporting information online at www.pnas.org/cgi/content/full/0911570106/DCSupplemental.